Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase ...

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

U.S. District Judge Jon S. Tigar entered a judgment for ChemoCentryx Inc. on Aug. 15, writing that all of the statements the shareholder plaintiff had alleged were false or misleading were opinions ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. The bear market induced by the Federal Reserve’s monetary tightening ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics Inc. advanced stock charts by Barron's. View 1AKRO historical stock data and compare to other stocks, and exchanges.

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor ...

Akero Therapeutics (AKRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the ...

In a recent move at Akero Therapeutics, Inc. (NASDAQ: AKRO), Chief Development Officer Yale Catriona sold shares worth more than $150,000. The transaction, which took place on September 20, 2024, ...

Akero Therapeutics (NASDAQ: AKRO) stock is soaring 120% and is one of today’s top trending tickers on sites like Yahoo Finance. The rally was sparked by the company’s release of positive data ...